Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression (NCT04935619)
Effects of Extended Cannabis Abstinence on Clinical and Cognitive Outcomes in Patients With Co-Morbid Major Depressive and Cannabis Use Disorders
🩺 Plain-English Summary (8th-Grade Level)
The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.
Who can join: Review the eligibility criteria below.
Location: Centre for Addiction and Mental Health — Toronto, Ontario
Age range: 18 Years to 55 Years
🧪 Interventions in This Study
- Contingency Reinforcement (BEHAVIORAL)
- Non-Contingency Reinforcement (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Centre for Addiction and Mental Health — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 535-8501
Email: maryam.sorkhou@mail.utoronto.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Cannabis Use
- Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder — Aurora, Colorado
- Feasibility/Acceptability of a Brief Motivational Intervention for Frequent/High-Intensity Cannabis Use — Seattle, Washington
- Acute Effects of Cannabis on Cognition and Affect — Pullman, Washington
- Research Investigating Drug Effects-2 (RiDE-2) — Chicago, Illinois
- Smart Talk: Cannabis Awareness and Prevention Curriculum Evaluation — Palo Alto, California
- Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis — Lexington, Kentucky
Explore by condition: All Cannabis Use clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.